20-F: PainReform Ltd. Files 20-F Report, Details Financials and Ongoing Clinical Trials

PainReform Ltd. released its 20-F filing, outlining its financial status, ongoing clinical trials for PRF-110, and potential risks.

Summary

• PainReform Ltd., a clinical-stage pharmaceutical company, has filed its 20-F report for the fiscal year ended December 31, 2023.
• The company is focused on reformulating established therapeutics to provide extended post-surgical pain relief.
• Their lead product candidate, PRF-110, is currently in Phase 3 clinical trials.
• The company has incurred significant losses since its inception, with net losses of approximately $9.3 million in 2023, $8.8 million in 2022, and $7.2 million in 2021.
• As of December 31, 2023, the company's cash and cash equivalents totaled $8.0 million.
• The company believes it has sufficient resources to fund operations through the third quarter of 2024 and will need to raise additional capital.
• A reverse share split of 1-for-10 was effected on June 8, 2023.
• The company is an emerging growth company and has taken advantage of certain exemptions from reporting requirements.
• The company's independent auditor included a going concern explanatory paragraph in its report, indicating substantial doubt about the company's ability to continue as a going concern.
• The company initiated its first Phase 3 clinical trial of PRF-110 in March 2023 for bunionectomy patients and expects to enroll up to 415 patients.
• A second Phase 3 trial for hernia repair operations is planned following the successful completion of the bunionectomy trial.
• The company is dependent on the success of PRF-110 and faces risks related to clinical trial outcomes, regulatory approvals, and competition.
• The company is subject to risks related to its operations in Israel, particularly due to the ongoing war between Israel and Hamas.
• The company is also subject to anti-bribery, anti-corruption, and anti-money laundering laws.
• The company is committed to doing business in accordance with applicable anti-corruption laws and its own internal policies and procedures.
• The company is exposed to risks relating to the laws of various countries as a result of its international operations.
• The company is exposed to various levels of political, economic, legal and other risks and uncertainties associated with operating in or exporting to other jurisdictions.
• The company is subject to anti-bribery, anti-corruption, and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act.
• The company is committed to doing business in accordance with applicable anti-corruption laws and its own internal policies and procedures.
• The company is exposed to risks relating to the laws of various countries as a result of its international operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is progressing with clinical trials, its financial situation is precarious, and there are significant risks associated with its operations and the industry it operates in.

Positives

• PRF-110 has shown substantial pain reduction for up to 72 hours post-operatively in a Phase 2 proof-of-concept clinical study.
• PRF-110 is based on ropivacaine, a safe and well-characterized local analgesic agent, and other components classified as GRAS by the FDA.
• The company has shifted manufacturing and scale-up operations of PRF-110 to North America.
• The company has an IND for PRF-110 and has initiated Phase 3 trials for the treatment of post-operative pain.
• The company is committed to doing business in accordance with applicable anti-corruption laws and its own internal policies and procedures.

Negatives

• The company has incurred significant losses since its inception.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company believes it has sufficient resources to fund operations through the third quarter of 2024 and will need to raise additional capital.
• The company is dependent on the success of PRF-110 and faces risks related to clinical trial outcomes, regulatory approvals, and competition.
• The company is dependent on a single supplier for some critical materials and components used in the manufacturing of PRF-110.
• The company is subject to risks related to its operations in Israel, particularly due to the ongoing war between Israel and Hamas.

Risks

• The company's ability to continue as a going concern is in doubt.
• The company is dependent on the success of PRF-110, which is still in clinical trials.
• The company has limited experience in conducting and managing clinical trials.
• The company relies on third parties for clinical trials, product manufacturing, and development.
• The company faces competition from other pharmaceutical companies.
• The company is subject to regulatory requirements relating to the development and marketing of its product candidates.
• The company's operations in Israel are subject to conditions in the Middle East.
• The company's international clinical trials may be delayed or adversely impacted by social, political, and economic factors.
• The company is subject to anti-bribery, anti-corruption, and anti-money laundering laws.
• The company is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.

Future Outlook

The company plans to continue clinical development of PRF-110, seek regulatory approvals, and potentially expand its product base through acquisitions or licensing arrangements.

Industry Context

The company operates in the competitive post-operative pain treatment market, which is estimated to reach $16 billion in North America and $45 billion worldwide by the end of 2026.

Comparison to Industry Standards

• PRF-110, if successfully developed and commercially launched, will compete with both currently marketed and new products marketed by other companies.
• Some of these potential competing drugs are already commercialized or are further advanced in development than PRF-110.
• The company will compete with Exparel (bupivacaine liposome injectable suspension, marketed by Pacira Pharmaceuticals, Inc.), Zynrelief a bupivacaine formulation marketed by Heron Therapeutics Inc., which also contains a synthetic polymer and a small amount of a nonsteroidal anti-inflammatory drug, meloxicam, MARCAINE (bupivacaine, marketed by Hospira, Inc.) and generic forms of bupivacaine; NAROPIN (ropivacaine, marketed by Fresenius Kabi USA, LLC) and generic forms of ropivacaine; and potentially other products in development.
• Additional competitive development programs include: Posimir by Durect (DRRX), Xaracoll by Innocoll, Allay Therapeutics ATX-101, TLC590, from the Taiwan Liposome Company, Cali Biosciences developing an injectable ropivacaine formulation CPL-01 which is currently in phase III for bunion and hernia; and Vertex pharmaceuticals, which completed phase III clinical studies in abdominoplasty and bunionectomy with VX-548, a selective NaV1.8 inhibitor.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment.
• Employees face uncertainty due to the company's financial instability.
• Customers (patients) may benefit from a successful PRF-110 product, but its availability is uncertain.
• Suppliers and creditors face the risk of non-payment due to the company's financial situation.

Next Steps

• Complete the ongoing Phase 3 clinical trial of PRF-110 for bunionectomy patients.
• Initiate a second Phase 3 clinical trial for hernia repair operations following successful completion of the bunionectomy trial.
• Seek regulatory approvals for PRF-110.
• Potentially expand the product base through acquisitions or licensing arrangements.
• Launch PRF-110 either by themselves or with a strategic partner that is experienced in marketing products in surgical environments.

Key Dates

Keywords

PRF-110, clinical trials, post-operative pain, ropivacaine, PainReform, financial results, 20-F filing, pharmaceutical, emerging growth company, Israel